ClinicalTrials.gg
RecruitingNCT07542756Updated Sep 16, 2026

A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

A Phase 4 interventional study of Sleep Hygiene Education and Melatonin IR, 3 mg in Insomnia, Insomnia Disorder and Chronic Insomnia, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by University of Pennsylvania · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania — 3 open to participants now, 4 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · University of Pennsylvania.

Planned enrollment
Largest of 22
1,200 · median 36
Started
2026
the only one that year
Phase 4
3 of 24
1 open now
Registered
24th of 24
by date

Among the 24 studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania, this one has the largest planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 4, and was the 24th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

3 of the 24 studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Sleep Initiation and Maintenance Disorders by University of Pennsylvania, or all of them as a file.
02

Study summary

The purpose of this study is to assess the relative effectiveness, safety, and durability of the most commonly used prescription (zolpidem, trazodone) and over-the-counter (OTC) (melatonin, diphenhydramine) medications for insomnia, as well as a less commonly used prescription that may have a better risk/benefit profile (doxepin).

Read the detailed description

Nearly 50% of primary care patients report symptoms of insomnia (e.g., problems initiating and/or maintaining sleep). Such sleep-related difficulties can presage new onset comorbid illness, as well as exacerbate, and be exacerbated by, existing comorbid illnesses. Accordingly, effectively treating insomnia in primary care patients is an untapped means towards the promotion of better public health.

Research Question:

While cognitive behavioral therapy for insomnia (CBT-I) is considered the first-line treatment, most patients (particularly those in primary care) do not have access to this form of therapy.

Instead, the majority of treated patients are using over-the-counter medications (OTCs), including melatonin and diphenhydramine (e.g., Benadryl), or are prescribed hypnotics (most commonly trazodone or zolpidem [e.g., Ambien]). Surprisingly, little is known about the absolute or relative effectiveness and safety of these commonly used medications, and of the often used medications, only Ambien is approved/recommended by the FDA and professional medical or sleep medicine societies. There are also limited data on which of these medical strategies has the best risk/benefit profile or is most acceptable to patients. The investigators' recent evaluation of FDA-approved medications for insomnia suggests doxepin, which is less commonly prescribed, has the most optimal risk/benefit profile. Multiple agencies have called for rigorous comparative effectiveness studies addressing these knowledge gaps, including the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health (NIH), and the Patient-Centered Outcomes Research Institute (PCORI). Moreover, the investigators' feedback from stakeholders shows that the need for such data is not just a professional practice concern, but shared by primary care patients and clinicians. Thus, evidence-based guidance on the management of insomnia with OTC and prescriptive medications is urgently needed.

Protocol Synopsis:

The investigators propose to conduct a large-scale, double blinded, placebo-controlled sequential multiple assignment randomized trial (SMART) comparing the relative effectiveness and safety of over-the counter medications commonly used by patients to treat their insomnia (i.e., diphenhydramine and melatonin) and prescriptive medications that are either commonly prescribed by clinicians (i.e., zolpidem and trazodone) or less commonly used, but may have a more optimal risk/benefit profile (i.e., doxepin). All conditions will use a nightly dosing strategy and include sleep hygiene education. To better align with current practice, participants who tolerate an initial lower medication dose but do not exhibit a treatment response will increase to a higher dose after 2 weeks. Treatment responders at 1 month will be followed for up to 6 months to understand longer-term maintenance of treatment benefits. The SMART design will re-randomize treatment non-responders at 1 month to an alternative arm (with each successive treatment non-response), providing all participants the opportunity to secure a treatment response with one of the study medications. To maintain blinding, participants will be instructed to take each medication (including placebo) 30 minutes prior to bed and all medications will be manufactured by a central Pharmacy to appear identical. All participants will be further instructed to be in bed for a period of 7-9 hours to both promote safety and potentially increase medication effects on early morning awakening and total sleep time.

03

Conditions studied

  • Insomnia
  • Insomnia Disorder
  • Chronic Insomnia
  • Chronic Insomnia Disorder

Keywords

  • Sleep
  • Insomnia
  • Zolpidem
  • Diphenhydramine
  • Doxepin
  • Melatonin
  • Trazodone
  • Placebo
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-80 years.
  • Meet criteria for Insomnia Disorder.
  • Score ≥15 on the Insomnia Severity Index (ISI).
  • Sleep initiation and/or maintenance complaints: ≥30 minutes in duration, occurring ≥3 nights/week, with a duration of ≥3 months.
  • Willingness to discontinue use of all sleep-related medications prior to enrollment.
  • Completion of a 2-week before starting any study medication.
  • Willingness to provide clinician assent for participation.

Exclusion criteria

Exclusion Criteria

Patients will be ineligible if they meet any of the following criteria: self-reported daytime napping (≥1 hour per day on ≥3 days per week); a history of suicidal attempts or current ideation, acute or chronic psychiatric or medical condition not controlled by therapy (according to their primary care physician), or current alcohol or drug misuse; or the diagnoses of (or high risk for) other sleep disorders, including circadian rhythm disorders (phase advance or phase delay syndromes), shift work related sleep disorder ("day sleepers" who work \~11pm to 7am) and those with rotating shiftwork schedules. To determine eligibility, all subjects will be screened using a multitier process including: an online screener; an intake interview; a review of the subjects EMR; and, finally, the receipt of the patient's PCP's assent. The following provides additional listing and details (AD) for the Exclusion Criteria:

General Considerations

  • Age \< 18 or > 80 years old
  • Inadequate English language comprehension
  • Minimal facility with smartphones, computers, i-Pads, or the internet.

Women's Health Given the potential for teratogenic effects with at least trazodone (FDA Class C), women intending to become pregnant, or who are pregnant, or who are breastfeeding will not be eligible for the study. Women will be asked to confirm the use of using self-report and, if applicable, by providing evidence of contraceptive medication (e.g., prescription or pill pack). We will perform a urine pregnancy test at baseline for female participants who are of reproductive age to confirm eligibility. At study enrollment, participants will be told to alert the study team and stop taking study medications if they become pregnant. Participants will be asked to test for pregnancy in the event of a missed cycle.

Medical and Psychiatric Considerations

  • Acute or unstable psychiatric conditions
  • Unstable medical condition, significant medical disorder, or acute illness (as determined by their PCP), within one month prior to the study period.
  • Significant liver or kidney problems
  • Pheochromocytoma or porphyria ( for trazodone)
  • Epilepsy or Seizure Disorder (contraindicated for trazodone)
  • Glaucoma or urinary retention (contraindicated for doxepin)
  • Increased ocular pressure (contraindicated for diphenhydramine)
  • Diagnosis of alcohol or substance use disorder within 2 years prior to the screening visit
  • Inability to refrain from drinking alcohol or substance use for at least 3 consecutive days

Sleep Disorders and Sleep Habits

  • Any lifetime history of (diagnosis of) breathing disorders, including and sleep apnea.
  • Shift work related sleep disorder (work \~11pm to 7am and "day sleeper") and rotating shiftwork schedules
  • Circadian rhythm disorders (phase advance or phase delay syndromes)
  • Self-reported usual daytime napping ≥1 hour per day (3 or more days per week)

Medications and Concomitant meds

  • Known or contraindication to study drugs
  • Known hypersensitivity or contraindication to drugs of the same class as the study treatments
  • Known hypersensitivity or contraindication to any of the study drug formulation
  • Treatment with CNS active drugs prohibited by the protocol for five half-lives of the respective drug (or 2 weeks)

Lifestyle

  • Heavy tobacco use (≥1 pack of cigarettes a day or inability to refrain from smoking during the night)
  • Not able or willing to stop treatment with moderate or strong cytochrome P450 3A4 () inhibitors
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Melatonin

    Nightly 30 minutes prior to bed (3 or 5 mg)

    Other: Sleep Hygiene Education · Dietary Supplement: Melatonin IR, 3 mg · Dietary Supplement: Melatonin IR, 5 mg

  • Placebo comparator
    Placebo

    Nightly 30 minutes prior to bed

    Other: Sleep Hygiene Education · Drug: Placebo

  • Experimental
    Diphenhydramine

    Nightly 30 minutes prior to bed (25 or 50 mg). Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.

    Other: Sleep Hygiene Education · Drug: Diphenhydramine, 25 mg · Drug: Diphenhydramine, 50 mg

  • Experimental
    Zolpidem

    Nightly 30 minutes prior to bed (5 or 10 mg)

    Other: Sleep Hygiene Education · Drug: Zolpidem, 5 mg · Drug: Zolpidem, 10 mg

  • Experimental
    Doxepin

    Nightly 30 minutes prior to bed (3 or 6 mg)

    Other: Sleep Hygiene Education · Drug: Doxepin, 3 mg · Drug: Doxepin, 6 mg

  • Experimental
    Trazodone

    Nightly 30 minutes prior to bed (50 or 100 mg)

    Other: Sleep Hygiene Education · Drug: Trazodone, 50 mg · Drug: Trazodone, 100 mg

Interventions

  • OtherSleep Hygiene Education

    Standard behavioral and environmental recommendations aimed at promoting healthy sleep

    Also known as: Sleep Hygiene

  • Dietary supplementMelatonin IR, 3 mg

    Immediate release formulation of melatonin, once nightly 30 minutes prior to bed

    Also known as: Acetyl-5-methoxytryptamine

  • Dietary supplementMelatonin IR, 5 mg

    Immediate release formulation of melatonin, once nightly 30 minutes prior to bed

    Also known as: Acetyl-5-methoxytryptamine

  • DrugDiphenhydramineStudies of DiphenhydramineDiphenhydramine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Diphenhydramine 25 mg, once nightly 30 minutes prior to bed. Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.

    Also known as: Benadryl

  • DrugDiphenhydramineStudies of DiphenhydramineDiphenhydramine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Diphenhydramine, 50 mg, once nightly 30 minutes prior to bed. Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.

    Also known as: Benadryl

  • DrugDoxepinStudies of DoxepinDoxepin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Doxepin, 3 mg, once nightly 30 minutes prior to bed

    Also known as: Silenor

  • DrugDoxepinStudies of DoxepinDoxepin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Doxepin, 6 mg, once nightly 30 minutes prior to bed

    Also known as: Silenor

  • DrugTrazodoneStudies of TrazodoneTrazodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trazodone, 50 mg, once nightly 30 minutes prior to bed

    Also known as: Desyrel

  • DrugTrazodoneStudies of TrazodoneTrazodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Trazodone, 100 mg, once nightly 30 minutes prior to bed

    Also known as: Desyrel

  • DrugPlacebo

    Placebo, once nightly 30 minutes prior to bed

    Also known as: Inactive Drug, Inert Capsule

  • DrugZolpidemStudies of ZolpidemZolpidem pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Zolpidem, 5 mg, once nightly 30 minutes prior to bed

    Also known as: Ambien

  • DrugZolpidemStudies of ZolpidemZolpidem pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Zolpidem, 10 mg, once nightly 30 minutes prior to bed

    Also known as: Ambien

06

What researchers measure

Primary outcomes

  1. Relative treatment response rates during acute (1-month) treatment phase

    Defined as an at least 8-point reduction on the Insomnia Severity Index (ISI)

    Time frame: From treatment initiation to 1 month after treatment initiation

  2. Relative safety and tolerability based on side effects during acute (1-month) treatment phase

    Percent of participants who experience 1 or more side effect(s), as well as the average number of events, incidence rate, and severity of events for each medication, as assessed by self-report (spontaneous and based on a weekly medical symptoms checklist)

    Time frame: From treatment initiation to 1 month after treatment initiation

  3. Relative effects on daytime symptoms and function during acute (1-month) treatment phase

    As measured by the Functional Outcomes of Sleep Questionnaire (FOSQ- 10). Min. score: 5, Max Score: 20 Lower score = more functional impairment Higher score = less functional impairment

    Time frame: From treatment initiation to 1 month after treatment initiation

  4. Durability of treatment response during longer-term maintenance (1-6 months) treatment phase

    Among initial treatment responders based on Insomnia Severity Index (ISI) and tolerability, the percent of subjects who continue to exhibit an ISI-based treatment response

    Time frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation

  5. Relative safety and tolerability based on side effects during longer-term maintenance (1-6 months) phase

    Among initial treatment responders based on ISI and tolerability, percent of participants who experience 1 or more side effect(s), as well as the average number of events, incidence rate, and severity of events for each medication, as assessed by self-report (spontaneous and based on a weekly medical symptoms checklist)

    Time frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation

  6. Durability of effects on daytime symptoms and function during longer-term maintenance (1-6 months) phase

    Among initial treatment responders based on Insomnia Severity Index (ISI) and tolerability, the relative improvements in on the Functional Outcomes of Sleep Questionnaire (FOSQ- 10). Min. score: 5, Max Score: 20. Lower score = more functional impairment, higher score = less functional impairment

    Time frame: From the start of the 2nd month after treatment initiation to 6 months after treatment initiation

Secondary outcomes

  1. Sleep Latency (SL)

    Average self-reported Sleep Latency (SL), per sleep diary entries

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  2. Wake After Sleep Onset (WASO)

    Average self-reported Wake After Sleep Onset (WASO), per sleep diary entries

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  3. Sleep Duration/Total Sleep Time (TST)

    Average total sleep time (TST), calculated from daily sleep diaries

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  4. Self-Reported Daytime Insomnia Symptoms

    As measured by The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ). Min. score: 0, Max score: 140. Lower score = less daytime insomnia symptoms/impairment, Higher score = more daytime insomnia symptoms/impairment

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  5. Self-Reported Daytime Sleepiness

    As measured by the Epworth Sleepiness Scale (ESS) Min. score: 0, Max score: 24 Lower score = less daytime sleepiness Higher score = more daytime sleepiness

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  6. Self-Reported Fatigue

    As measured by the Brief Fatigue Inventory (BFI). Min. score: 0, Max score: 10. Lower score = less fatigue, higher score = more fatigue

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  7. Self-Reported Depression

    As measured by the Patient Health Questionnaire (PHQ-9). Min. score: 0, max score: 27. Lower score = less depression, higher score = more depression

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  8. Self-Reported Anxiety

    As measured by the General Anxiety Disorder-7 (GAD-7). Min. score: 0, max score: 21. Lower score = less anxiety, higher score = more anxiety

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  9. Cognitive Dysfunction and Residual Sedation

    As measured by the 90-second Digit Symbol Substitution Test (DSST). Min. score: 0, max score: 120. Lower score = more cognitive dysfunction \& residual sedation, higher score = less cognitive dysfunction \& residual sedation

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  10. Attention/Fatigue

    As measured by number of lapses and mean reaction time on a 3-minute Psychomotor Vigilance Test (PVT). Min. lapses: 0, max lapses: 45. Less lapses = better performance (better attention, less fatigue), more lapses = worse performance (worse attention, more fatigue). Min mean reaction time: 100 ms, max mean reaction time: 500 ms. Lower mean reaction time = better performance (better attention, less fatigue), higher mean reaction time = worse performance (worse attention, more fatigue)

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  11. Self-Reported Quality of Life

    As measured by The 12-item Short Form Survey (SF-12) Min: 0, Max: 100 (normed to population scores). Lower score = worse quality of life, higher score = better quality of life

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  12. Self-Reported State Alertness Versus Sleepiness

    As measured by the Karolinska Sleepiness Scale (KSS), a single-item measure of state alertness versus sleepiness, administered twice daily. The item is a Likert-scale with a range of 1 (extremely alert) to 9 (very sleepy), with lower scores representing higher levels of state alertness and higher scores representing higher levels of state sleepiness.

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

  13. Sleep Continuity, Activity and Caloric Expenditure

    As measured by a Fitbit, a commercially-available wearable device that utilizes movement detection and heart rate measurements to make sleep/wake assessments every 60 seconds, as well as hourly measures of heart rate, diurnal activity levels, and inferential measures of caloric expenditure.

    Time frame: From baseline (prior to treatment), to the end of 1 month of treatment (acute treatment phase) and from the start of the 2nd month after treatment initiation to 6 months after treatment initiation (longer-term maintenance phase in responders)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Following the trial, the study's de-identified data will be made available for archival analyses (first to study site investigators and then to all interested clinical investigators) consistent with PCORI data sharing policies: "Data collected as part of this research project will be de-identified and such de-identified data to be used for secondary research purposes and shared with researchers not affiliated with the institution conducting the research project." All shared data sets will be de-identified and will only retain a code that indicates the order in which the patient was enrolled and their site of origination. PCORI must approve all sharing of information/data prior to its occurrence.

Supporting information: Study protocol, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2032, 68 months after the start.

Of 53 non-industry phase 4 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 59. This study's planned 68 months is above that.

Counting every sponsor, half of 58 studies reached it within 28 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Apr 21, 2026
StartActual
May 1, 2026
Primary completionEst.
Jan 1, 2032
CompletionEst.
Jan 1, 2032
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07542756
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
May 1, 2026
Primary completion
Jan 1, 2032 (estimated)
Completion
Jan 1, 2032 (estimated)
Last update
Sep 16, 2026

Study contacts

Michael L Perlis, PhD
Contact
mperlis@upenn.edu
215-746-3577
Mark Seewald, MSW
Contact
mark.seewald@pennmedicine.upenn.edu
215-746-4378
Michael L Perlis, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Diphenhydramine · Doxepin · Trazodone · Zolpidem

Start the discussion